SAPPORO CLINICAL LABORATORY INC.JP:9776
Market cap
¥8.3B
P/E ratio
12.2x
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Depreciation & amortization | 334 | 303 | 334 | 342 | 309 | 245 | 271 | 547 | 519 | 536 | 559 |
| Cash from operations | 610 | 942 | 670 | 1,310 | 647 | 1,256 | 838 | 1,574 | 1,430 | 1,078 | 731 |
| Capital expenditures | -313 | -474 | -546 | -300 | -243 | -2,974 | -3,142 | -838 | -811 | -388 | -1,222 |
| Cash from investing | -449 | -455 | -530 | -293 | -80 | -2,913 | -3,148 | -831 | -409 | -395 | -1,240 |
| Payments for dividends | -44 | -42 | -38 | -35 | -38 | -34 | -34 | -79 | -77 | -77 | -77 |
| Repurchases of common stock | -406 | -0 | -0 | -32 | -96 | -0 | - | -95 | -29 | - | -190 |
| Proceeds from issuance of term debt, net | - | - | - | - | - | - | 2,000 | - | - | - | - |
| Repayments of term debt | -30 | -25 | -22 | -13 | - | - | - | -134 | -134 | -132 | -135 |
| Cash from financing | -496 | -83 | -74 | -95 | -146 | -52 | 1,944 | -113 | -348 | -370 | -526 |
| Free cash flow | |||||||||||
| FCF margin (%) |